INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL

For further information, please contact: Dan Suesskind, Chief Financial Officer	Teva Pharmaceutical Industries Ltd.		972-2-941-1717
George Barrett, Corp. E. V.P. - Global pharmaceutical Markets Chief Executive Officer		Teva Pharmaceutical Industries Ltd. Teva North America	(215) 591-3030
Liraz Kalif / Kevin Mannix, Investor Relations		Teva Pharmaceutical Industries Ltd. Teva North America	972-3-926-7281 (215) 591-8912
Sven Andréasson President & CEO		Active Biotech	+46 46 19 20 49
Tomas Leanderson Chief Scientific Officer		Active Biotech	+46 46 19 20 95
Cecilia Hofvander Manager Corporate Communication		Active Biotech	+46 46 19 11 22

INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS